Skip to main content
Premium Trial:

Request an Annual Quote

Myriad to Co-market Sividon Breast Cancer Test

NEW YORK (GenomeWeb News) – Myriad Genetics GmbH and Sividon Diagnostics today announced a deal granting Myriad the exclusive rights to co-market Sividon's EndoPredict prognostic test kit for breast cancer patients outside the US.

The deal leverages Myriad's 45-person international commercial team and will "significantly increase" the number of medical specialists and sales professionals supporting EndoPredict, according to the companies.

Myriad Genetics GmbH is the international subsidiary of Myriad Genetics and is based in Zurich.

EndoPredict, a second-generation multigene test kit for patients who have been diagnosed with breast cancer, detects the likelihood of metastases and helps guide treatment with chemotherapy as well as extended anti-hormone therapy. Therapeutic decisions based on EndoPredict results "confer a high level of diagnostic safety," Myriad and Sividon said, adding that in multiple clinical outcome studies with more than 2,200 patients, the test accurately predicted cancer-specific disease progression and metastases.

"Myriad has a significant opportunity to leverage our international presence, and we are pleased to be partnering with Sividon to make EndoPredict even more widely available to patients in Europe and worldwide," Gary King, executive vice president of international operations for Myriad Genetics, said in a statement.

Financial and other terms of the deal were not disclosed.

Based in Cologne, Germany, Sividon was founded in 2010 through a management buyout from Siemens Healthcare Diagnostics and develops methods for molecular pathology laboratories to improve care for cancer patients.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.